Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa Trial to Evaluate Epcoritamab Administered Before and After CAR-T Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphomas

NCT06458439 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT06458439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06458439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa Trial to Evaluate Epcoritamab Administered Before and After CAR-T Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphomas
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Phase 2
Overall status
Recruiting
Start date
September 24, 2024
Completion date
December 31, 2027
Enrollment
31 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade b-cell lymphoma, lymphoma, non-hodgkin, refractory diffuse large b-cell lymphoma, relapsed diffuse large b cell lymphoma, transformed indolent non-hodgkin lymphoma to diffuse large b-cell lymphoma